HPP⁺

HPP⁺
Clinical data
Other names	Haloperidol pyridinium; Haloperidol pyridinium ion; Haloperidol pyridinium cation; BCPP+; 4-CFOBP; 4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)pyridinium
Drug class	Monoaminergic neurotoxin
ATC code	None;
Identifiers
	IUPAC name 4-[4-(4-chlorophenyl)pyridin-1-ium-1-yl]-1-(4-fluorophenyl)butan-1-one;
CAS Number	125785-69-5;
PubChem CID	9975463;
DrugBank	DBMET01212;
ChemSpider	8151055;
UNII	47Z7A2W953;
ChEBI	CHEBI:178132;
ChEMBL	ChEMBL1269;
CompTox Dashboard (EPA)	DTXSID00154895 ;
Chemical and physical data
Formula	C21H18ClFNO+
Molar mass	354.83 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC=C1C2=CC=[N+](C=C2)CCCC(=O)C3=CC=C(C=C3)F)Cl;
	InChI InChI=1S/C21H18ClFNO/c22-19-7-3-16(4-8-19)17-11-14-24(15-12-17)13-1-2-21(25)18-5-9-20(23)10-6-18/h3-12,14-15H,1-2,13H2/q+1; Key:KAPIKUHBALFONG-UHFFFAOYSA-N;

HPP⁺, also known as haloperidol pyridinium, is a monoaminergic neurotoxin and a metabolite of haloperidol.^[1]^[2]^[3]

^ Kostrzewa RM (2022). "Survey of Selective Monoaminergic Neurotoxins Targeting Dopaminergic, Noradrenergic, and Serotoninergic Neurons". Handbook of Neurotoxicity. Cham: Springer International Publishing. pp. 159–198. doi:10.1007/978-3-031-15080-7_53. ISBN 978-3-031-15079-1.
^ Igarashi K (1998). "The Possible Role of an Active Metabolite Derived from the Neuroleptic Agent Haloperidol in Drug-Induced Parkinsonism". Journal of Toxicology: Toxin Reviews. 17 (1): 27–38. doi:10.3109/15569549809006488. ISSN 0731-3837.
^ Górska A, Marszałł M, Sloderbach A (October 2015). "[The neurotoxicity of pyridinium metabolites of haloperidol]" [The neurotoxicity of pyridinium metabolites of haloperidol]. Postepy Higieny I Medycyny Doswiadczalnej (in Polish). 69: 1169–1175. doi:10.5604/17322693.1175009 (inactive 12 July 2025). PMID 26561842.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)